These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 16442912)

  • 21. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Kenchaiah S; Pocock SJ; Wang D; Finn PV; Zornoff LA; Skali H; Pfeffer MA; Yusuf S; Swedberg K; Michelson EL; Granger CB; McMurray JJ; Solomon SD;
    Circulation; 2007 Aug; 116(6):627-36. PubMed ID: 17638930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sex Differences in New York Heart Association Functional Classification and Survival in Acute Heart Failure Patients With Preserved or Reduced Ejection Fraction.
    Kajimoto K; Sato N;
    Can J Cardiol; 2020 Jan; 36(1):30-36. PubMed ID: 31759787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of serum digoxin concentration and outcomes in patients with heart failure.
    Rathore SS; Curtis JP; Wang Y; Bristow MR; Krumholz HM
    JAMA; 2003 Feb; 289(7):871-8. PubMed ID: 12588271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relation of sex to morbidity and mortality in patients with heart failure and reduced or preserved left ventricular ejection fraction.
    Alla F; Al-Hindi AY; Lee CR; Schwartz TA; Patterson JH; Adams KF
    Am Heart J; 2007 Jun; 153(6):1074-80. PubMed ID: 17540212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
    Solomon SD; Dobson J; Pocock S; Skali H; McMurray JJ; Granger CB; Yusuf S; Swedberg K; Young JB; Michelson EL; Pfeffer MA;
    Circulation; 2007 Sep; 116(13):1482-7. PubMed ID: 17724259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study.
    Lund LH; Svennblad B; Melhus H; Hallberg P; Dahlström U; Edner M
    Circ Heart Fail; 2013 Mar; 6(2):174-83. PubMed ID: 23386667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial.
    Ahmed A; Rich MW; Fleg JL; Zile MR; Young JB; Kitzman DW; Love TE; Aronow WS; Adams KF; Gheorghiade M
    Circulation; 2006 Aug; 114(5):397-403. PubMed ID: 16864724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of all-cause mortality in chronic Chagas' heart disease in the current era of heart failure therapy.
    Theodoropoulos TA; Bestetti RB; Otaviano AP; Cordeiro JA; Rodrigues VC; Silva AC
    Int J Cardiol; 2008 Aug; 128(1):22-9. PubMed ID: 18258318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparative study on characteristics of congestive heart failure patients with preserved versus abnormal left ventricular systolic function and evaluation effects of therapy].
    Zhan H; Tse HF; Cao JM; Lau CP
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Apr; 18(4):210-5. PubMed ID: 16647010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction.
    Pavlović A; Polovina M; Ristić A; Seferović JP; Veljić I; Simeunović D; Milinković I; Krljanac G; Ašanin M; Oštrić-Pavlović I; Seferović PM
    Eur J Prev Cardiol; 2019 Jan; 26(1):72-82. PubMed ID: 30335505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the effects of cardiac resynchronization therapy in patients with class II versus class III and IV heart failure (from the InSync/InSync ICD Italian Registry).
    Landolina M; Lunati M; Gasparini M; Santini M; Padeletti L; Achilli A; Bianchi S; Laurenzi F; Curnis A; Vincenti A; Valsecchi S; Denaro A;
    Am J Cardiol; 2007 Sep; 100(6):1007-12. PubMed ID: 17826388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.
    Wikstrand J; Wedel H; Castagno D; McMurray JJ
    J Intern Med; 2014 Feb; 275(2):134-43. PubMed ID: 24118421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heart failure with preserved left ventricular ejection fraction in patients with acute myocardial infarction.
    Antonelli L; Katz M; Bacal F; Makdisse MR; Correa AG; Pereira C; Franken M; Fava AN; Serrano Junior CV; Pesaro AE
    Arq Bras Cardiol; 2015 Aug; 105(2):145-50. PubMed ID: 26039659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcomes in patients with ambulatory new york heart association class III and IV heart failure undergoing cardiac resynchronization therapy.
    Rickard J; Bassiouny M; Tedford RJ; Baranowski B; Spragg D; Cantillon D; Varma N; Wilkoff BL; Tang WH
    Am J Cardiol; 2015 Jan; 115(1):82-5. PubMed ID: 25491007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative potential of the 2-item versus the 9-item patient health questionnaire to predict death or rehospitalization in heart failure.
    Piepenburg SM; Faller H; Gelbrich G; Störk S; Warrings B; Ertl G; Angermann CE
    Circ Heart Fail; 2015 May; 8(3):464-72. PubMed ID: 25878325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
    Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
    J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure.
    Ghali JK; Boehmer J; Feldman AM; Saxon LA; Demarco T; Carson P; Yong P; Galle EG; Leigh J; Ecklund FL; Bristow MR
    J Card Fail; 2007 Nov; 13(9):769-73. PubMed ID: 17996827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.